Paul Fitzgerald is an Endocrinology/Metabolic physician. OpenAlex indexes 9 publications with 531 citations (h-index 6); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
350 Parnassus Avenue
Suite 710
San Francisco, CA 94117
Telephone
415-665-1136Registry record last updated 23 Sept 2010.
Clinical trials
- A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
Sponsor: University of California, San Francisco
- Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
Sponsor: University of California, San Francisco
- International Study to Predict Optimised Treatment - in Depression
Sponsor: BRC Operations Pty. Ltd.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ASCEND THERAPEUTICS US, LLCProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
39.9%Statin13.8%Atorvastatin Calcium47%Rosuvastatin Calcium39%Simvastatin14%Part D<11 patientsAngiotensin receptor blocker (ARB)6.3%Losartan Potassium100%Part D≥14 patients+ 6 more classes in this area
Metabolism & gastrointestinal
14.1%Corticosteroid3.6%Prednisone100%Part D<11 patientsBiguanide (metformin)2.7%Metformin Hcl Er100%Part D<11 patients+ 4 more classes in this area
Hormonal (systemic)
12.5%l-Thyroxine12.5%Synthroid64%Levothyroxine Sodium36%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
9 NIH research awards on record, funded 1987–2026 per NIH RePORTER. The latest:
- Frequency and E-field Enhancement of iTBS for Depression (FREED)
University of California, San Diego
FY2026$557,314R33MH129471 - Frequency and E-field Enhancement of iTBS for Depression (FREED)
University of California, San Diego
FY2026$287,841R33MH129471 - Frequency and E-field Enhancement of iTBS for Depression (FREED)
University of California, San Diego
FY2024$749,530R61MH129471
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”